A consensus on the use of daylight photodynamic therapy in the UK

Sally Ibbotson; Robin Stones; Jonathan Bowling; Sandra Campbell; Stephen Kownack; Muthu Sivaramakrishnan; Ronan Valentine; Colin A. Morton

doi:10.1080/09546634.2016.1240863

A consensus on the use of daylight photodynamic therapy in the UK

Sally Ibbotson (Lead / Corresponding author), Robin Stones, Jonathan Bowling, Sandra Campbell, Stephen Kownack, Muthu Sivaramakrishnan, Ronan Valentine, Colin A. Morton

Undergraduate Medicine

Research output: Contribution to journal › Article › peer-review

18 Citations (Scopus)

400 Downloads (Pure)

Abstract

Background: Actinic keratoses (AKs) are a consequence of chronic exposure to ultraviolet radiation. Treatment of chronically photo-damaged skin and AKs is driven by risk of progression to squamous cell carcinoma, as well as for symptomatic relief. Conventional photodynamic therapy (c-PDT) is indicated when AKs are multiple or confluent and if patients respond poorly or are unable to tolerate other therapies. c-PDT is limited by the field size that can be treated in single sessions and can cause significant discomfort.

Objective: Recent studies investigated daylight illumination to activate protoporphyrin IX and daylight-PDT (d-PDT) is now licensed in the UK for face and scalp AKs. A group of experts met to discuss application of d-PDT with methyl aminolevulinate (MAL) and develop a UK consensus statement, specific to UK weather conditions.

Methods: The UK consensus recommendations were reached among eight experts, who reviewed recent studies on d-PDT, assessed UK meteorological data and discussed personal experiences of d-PDT for AKs.

Results: Recommendations from these discussions provide guidance on d-PDT use, specifically regarding patient selection, therapeutic indications, when to treat, skin preparation, MAL application and daylight exposure for patients with AKs.

Conclusions: This UK expert consensus provides practical guidance for UK application of d-PDT.

Original language	English
Pages (from-to)	360-367
Number of pages	8
Journal	Journal of Dermatological Treatment
Volume	28
Issue number	4
Early online date	22 Sept 2016
DOIs	https://doi.org/10.1080/09546634.2016.1240863
Publication status	Published - 2017

Keywords

Actinic keratosis
Daylight
Methyl aminolevulinate
Photodynamic therapy

Access to Document

10.1080/09546634.2016.1240863Licence: CC BY-NC-ND

Final Published Version
© 2016 The Author(s). Published by Informa UK Limited, trading as Taylor & Francis Group. This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License (http://creativecommons.org/licenses/by-nc-nd/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited, and is not altered, transformed, or built upon in any way.
Final published version, 1.21 MBLicence: CC BY-NC-ND

Cite this

@article{7afea6410e9346b09d0120d243ac9f1e,

title = "A consensus on the use of daylight photodynamic therapy in the UK",

abstract = "Background: Actinic keratoses (AKs) are a consequence of chronic exposure to ultraviolet radiation. Treatment of chronically photo-damaged skin and AKs is driven by risk of progression to squamous cell carcinoma, as well as for symptomatic relief. Conventional photodynamic therapy (c-PDT) is indicated when AKs are multiple or confluent and if patients respond poorly or are unable to tolerate other therapies. c-PDT is limited by the field size that can be treated in single sessions and can cause significant discomfort.Objective: Recent studies investigated daylight illumination to activate protoporphyrin IX and daylight-PDT (d-PDT) is now licensed in the UK for face and scalp AKs. A group of experts met to discuss application of d-PDT with methyl aminolevulinate (MAL) and develop a UK consensus statement, specific to UK weather conditions.Methods: The UK consensus recommendations were reached among eight experts, who reviewed recent studies on d-PDT, assessed UK meteorological data and discussed personal experiences of d-PDT for AKs.Results: Recommendations from these discussions provide guidance on d-PDT use, specifically regarding patient selection, therapeutic indications, when to treat, skin preparation, MAL application and daylight exposure for patients with AKs.Conclusions: This UK expert consensus provides practical guidance for UK application of d-PDT.",

keywords = "Actinic keratosis, Daylight, Methyl aminolevulinate, Photodynamic therapy",

author = "Sally Ibbotson and Robin Stones and Jonathan Bowling and Sandra Campbell and Stephen Kownack and Muthu Sivaramakrishnan and Ronan Valentine and Morton, {Colin A.}",

note = "This paper originates from a report of an advisory board on “UK Metvix daylight activated photodynamic therapy” held in Birmingham, UK, 12 November 2014. This meeting was organised and funded by Galderma UK, who selected the participants.",

year = "2017",

doi = "10.1080/09546634.2016.1240863",

language = "English",

volume = "28",

pages = "360--367",

journal = "Journal of Dermatological Treatment",

issn = "0954-6634",

publisher = "Informa Healthcare",

number = "4",

}

TY - JOUR

T1 - A consensus on the use of daylight photodynamic therapy in the UK

AU - Ibbotson, Sally

AU - Stones, Robin

AU - Bowling, Jonathan

AU - Campbell, Sandra

AU - Kownack, Stephen

AU - Sivaramakrishnan, Muthu

AU - Valentine, Ronan

AU - Morton, Colin A.

N1 - This paper originates from a report of an advisory board on “UK Metvix daylight activated photodynamic therapy” held in Birmingham, UK, 12 November 2014. This meeting was organised and funded by Galderma UK, who selected the participants.

PY - 2017

Y1 - 2017

N2 - Background: Actinic keratoses (AKs) are a consequence of chronic exposure to ultraviolet radiation. Treatment of chronically photo-damaged skin and AKs is driven by risk of progression to squamous cell carcinoma, as well as for symptomatic relief. Conventional photodynamic therapy (c-PDT) is indicated when AKs are multiple or confluent and if patients respond poorly or are unable to tolerate other therapies. c-PDT is limited by the field size that can be treated in single sessions and can cause significant discomfort.Objective: Recent studies investigated daylight illumination to activate protoporphyrin IX and daylight-PDT (d-PDT) is now licensed in the UK for face and scalp AKs. A group of experts met to discuss application of d-PDT with methyl aminolevulinate (MAL) and develop a UK consensus statement, specific to UK weather conditions.Methods: The UK consensus recommendations were reached among eight experts, who reviewed recent studies on d-PDT, assessed UK meteorological data and discussed personal experiences of d-PDT for AKs.Results: Recommendations from these discussions provide guidance on d-PDT use, specifically regarding patient selection, therapeutic indications, when to treat, skin preparation, MAL application and daylight exposure for patients with AKs.Conclusions: This UK expert consensus provides practical guidance for UK application of d-PDT.

AB - Background: Actinic keratoses (AKs) are a consequence of chronic exposure to ultraviolet radiation. Treatment of chronically photo-damaged skin and AKs is driven by risk of progression to squamous cell carcinoma, as well as for symptomatic relief. Conventional photodynamic therapy (c-PDT) is indicated when AKs are multiple or confluent and if patients respond poorly or are unable to tolerate other therapies. c-PDT is limited by the field size that can be treated in single sessions and can cause significant discomfort.Objective: Recent studies investigated daylight illumination to activate protoporphyrin IX and daylight-PDT (d-PDT) is now licensed in the UK for face and scalp AKs. A group of experts met to discuss application of d-PDT with methyl aminolevulinate (MAL) and develop a UK consensus statement, specific to UK weather conditions.Methods: The UK consensus recommendations were reached among eight experts, who reviewed recent studies on d-PDT, assessed UK meteorological data and discussed personal experiences of d-PDT for AKs.Results: Recommendations from these discussions provide guidance on d-PDT use, specifically regarding patient selection, therapeutic indications, when to treat, skin preparation, MAL application and daylight exposure for patients with AKs.Conclusions: This UK expert consensus provides practical guidance for UK application of d-PDT.

KW - Actinic keratosis

KW - Daylight

KW - Methyl aminolevulinate

KW - Photodynamic therapy

U2 - 10.1080/09546634.2016.1240863

DO - 10.1080/09546634.2016.1240863

M3 - Article

C2 - 27788605

SN - 0954-6634

VL - 28

SP - 360

EP - 367

JO - Journal of Dermatological Treatment

JF - Journal of Dermatological Treatment

IS - 4

ER -

A consensus on the use of daylight photodynamic therapy in the UK

Abstract

Keywords

Access to Document

Fingerprint

Cite this